Publications by authors named "Angela Vitrano"

Claim this Profile
Q
Quantifying Morbidity Risk Attributed to Red-Cell Transfusion Volume in Optimally Transfused Patients With β-Thalassemia.
Khaled M Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study.
Khaled M Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifetime Risk of Liver Disease in Patients With β-Thalassemia: Data From the de-LIGHT Retrospective Cohort Study.
Khaled M Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone

Eur J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Dominant p.Ser740* Pathogenic Variant in 20 Knowingly Unrelated Families Affected by Rod-Cone Dystrophy: Potential Founder Effect in Western Sicily.
Fabiana D'Esposito, Viviana Randazzo, Maria Igea Vega, Gabriella Esposito, Paolo Enrico Maltese, Angela Vitrano

Medicina (Kaunas)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Thalassemia International Prognostic Scoring System (TIPSS).
Angela Vitrano, Khaled M Musallam, Antonella Meloni, Mehran Karimi, Shahina Daar

Blood Cells Mol Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia.
Khaled M Musallam, Angela Vitrano, Antonella Meloni, Sebastiano Addario Pollina, Mehran Karimi

Am J Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia.
Khaled M Musallam, Angela Vitrano, Antonella Meloni, Sebastiano Addario Pollina, Vito Di Marco

Br J Haematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia.
Khaled M Musallam, Angela Vitrano, Antonella Meloni, Sebastiano Addario Pollina, Mehran Karimi

Haematologica· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A complication risk score to evaluate clinical severity of thalassaemia syndromes.
Angela Vitrano, Antonella Meloni, Walter Addario Pollina, Mehran Karimi, Amal El-Beshlawy

Br J Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Aurelio Maggio, Antonis Kattamis, Mariagrazia Felisi, Giorgio Reggiardo, Amal El-Beshlawy, Angela Vitrano

Lancet Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial.
Angela Vitrano, Giovan Battista Ruffo, Alessia Pepe, Domenico Giuseppe D'Ascola, Vincenzo Caruso

Br J Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-Thalassemia heterozygote state detrimentally affects health expectation.
Luciano Graffeo, Angela Vitrano, Salvatore Scondotto, Gabriella Dardanoni, Walter Sebastiano Pollina Addario

Eur J Intern Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET.
Angela Vitrano, Massimiliano Sacco, Rosamaria Rosso, Alessandra Quota, Daniela Fiorino

Eur J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left Ventricular Diastolic Dysfunction in β-Thalassemia Major with Heart Failure.
Luigi Mancuso, Angela Vitrano, Andrea Mancuso, Massimiliano Sacco, Antonietta Ledda

Hemoglobin· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The heterozygote state for β-thalassemia detrimentally affects health outcomes.
Luciano Graffeo, Angela Vitrano, Antonino Giambona, Salvatore Scondotto, Gabriella Dardanoni

Am J Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?
Angela Vitrano, Giuseppina Calvaruso, Eliana Lai, Grazia Colletta, Alessandra Quota

Br J Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
Angela Vitrano, Giuseppina Calvaruso, Lorenzo Tesé, Francesco Gioia, Filippo Cassarà

Eur J Haematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Giuseppina Calvaruso, Angela Vitrano, Rosario Di Maggio, Eliana Lai, Grazia Colletta

Am J Hematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Giusi Calvaruso, Angela Vitrano, Rosario Di Maggio, Samir Ballas, Martin H Steinberg

Blood Cells Mol Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Aldo Filosa, Angela Vitrano, Paolo Rigano, Giuseppina Calvaruso, Rita Barone

Blood Cells Mol Dis· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.
Aurelio Maggio, Angela Vitrano, Giuseppina Calvaruso, Rita Barone, Paolo Rigano

Blood Cells Mol Dis· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
Aurelio Maggio, Angela Vitrano, Gaetano Lucania, Marcello Capra, Liana Cuccia

Am J Hematol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Aurelio Maggio, Aldo Filosa, Angela Vitrano, Giuseppina Aloj, Antonis Kattamis

Blood Cells Mol Dis· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Gaetano Restivo Pantalone, Aurelio Maggio, Angela Vitrano, Marcello Capra, Liana Cuccia

Hemoglobin· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chelation treatment in sickle-cell-anaemia: much ado about nothing?
Gaetano Lucania, Angela Vitrano, Aldo Filosa, Aurelio Maggio

Br J Haematol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis